NASDAQ:IMMX

Immix Biopharma Stock Insider Trading

Healthcare > Biotechnology

Buy IMMX

*Your capital is at risk

$8.80

-1.45 (-14.15%)

At Close: Jul 20, 2026

Immix Biopharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.07. In total, the insiders bought 6.08M and sold 60K IMMX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.07
● Buy	6.08M shares
● Sell	60K shares
99% Buy Activity Strong Negative Correlation
Buy Signal High Confidence May 22, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 99.07. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (99% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 11, 2024 Buy	Stock Option (Right to Buy) A-Award	Ng Carey Director	Director	33 000 Value: $67.3K
Jun 11, 2024 Buy	Stock Option (Right to Buy) A-Award	Rachman Ilya M CEO And Chairman	CEO / President	340 000 Value: $693.6K
Jun 11, 2024 Buy	Stock Option (Right to Buy) A-Award	Hsu Jason Director	Director	33 000 Value: $67.3K
Jun 11, 2024 Buy	Stock Option (Right to Buy) A-Award	Chudnovsky Yekaterina	Director	33 000 Value: $67.3K
Jun 11, 2024 Buy	Stock Option (Right to Buy) A-Award	Marquet Magda Director	Director	33 000 Value: $67.3K
Jun 11, 2024 Buy	Stock Option (Right to Buy) A-Award	Adams Helen C. Director	Director	33 000 Value: $67.3K
Jun 07, 2024 Buy	Common Stock P-Purchase	Rachman Ilya M CEO And Chairman	CEO / President	2 600 Value: $6K
Jun 07, 2024 Buy	Common Stock P-Purchase	Morris Gabriel S CFO	C-Suite Officer	2 500 Value: $5K
Jun 07, 2024 Buy	Common Stock P-Purchase	Rachman Ilya M CEO And Chairman	CEO / President	2 600 Value: $6K
Jun 07, 2024 Buy	Common Stock P-Purchase	Morris Gabriel S CFO	C-Suite Officer	2 500 Value: $5K
Jun 04, 2024 Buy	Common Stock P-Purchase	Morris Gabriel S CFO	C-Suite Officer	3 300 Value: $6K
Jun 04, 2024 Buy	Common Stock P-Purchase	Rachman Ilya M CEO And Chairman	CEO / President	3 300 Value: $6K
Jun 04, 2024 Buy	Common Stock P-Purchase	Morris Gabriel S CFO	C-Suite Officer	3 300 Value: $6K
Jun 04, 2024 Buy	Common Stock P-Purchase	Rachman Ilya M CEO And Chairman	CEO / President	3 300 Value: $6K
May 20, 2024 Buy	Common Stock A-Award	Morris Gabriel S CFO	C-Suite Officer	24 141 Value: $0
May 20, 2024 Buy	Common Stock A-Award	Morris Gabriel S CFO	C-Suite Officer	24 141 Value: $0
May 20, 2024 Buy	Common Stock A-Award	Morris Gabriel S CFO	C-Suite Officer	194 218 Value: $0
May 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Buchan Jane Director	Director	20 436 Value: $50.5K
May 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Buchan Jane Director	Director	24 153 Value: $59.7K
May 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Ng Carey Director	Director	21 587 Value: $53.3K
May 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Ng Carey Director	Director	25 512 Value: $63.0K
May 15, 2024 Buy	Common Stock A-Award	Marquet Magda Director	Director	25 002 Value: $0
May 15, 2024 Buy	Common Stock A-Award	Buchan Jane Director	Director	1 332 Value: $0
May 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Buchan Jane Director	Director	20 436 Value: $50.5K
May 15, 2024 Buy	Common Stock A-Award	Buchan Jane Director	Director	1 332 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT IMMIX BIOPHARMA, INC.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the tr...

Read Full Profile Here